Floatz logo

Anti-Cd19/22-Car Vector-Transduced T Cells

B-Cell Chronic Lymphocytic Leukemia in Relapse (Diagnosis)

Chinese PLA General HospitalCell therapyPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the B-Cell Chronic Lymphocytic Leukemia in Relapse (Diagnosis) cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

Anti-Cd19/22-Car Vector-Transduced T Cells is also rated in:

Hematopoietic/Lymphoid CancerDormant
CCC
Indicative ·
48 / 100
View asset →
B-cell Adult Acute Lymphoblastic LeukemiaDormant
CC
Indicative ·
47 / 100
View asset →
Adult Acute Lymphoblastic Leukemia in RemissionDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →